Search
DEEN
more info

Contact:
Phone:+49 0761 1514 440Fax:+49 0761 1514 460Email:info[at]falkfoundation.org

    Falk Gastro Review Journal

    Current science, compiled for you from the multitude of scientific publications – this is the Falk Gastro Review Journal.

    Dunkel- bis hellblaue Grafik einer Tonspur-Frequenz auf orangem Hintergund.

    The latest issues

    Edition 4/2024

    read more

    Edition 3/2024

    read more

    Edition 2/2024

    read more

    Find here all FGR publications since mid-2022 selected and reviewed from international medical journals. Click here above to browse the individual quarterly issues or use the filters below or click chronologically through all articles.

    All articles

    Esophagus to Small Intestine

    A “new” option in Helicobacter pylori eradication: High-dose amoxicillin dual therapy outperforms bismuth quad-ruple therapy in a high dual resistance setting

    Helicobacter. 2023;28(3):e12962

    Macedo Silva V, Lima Capela T, Freitas M, Boal Carvalho P, Magalhães J, Cotter J

    Go to article

    Esophagus to Small Intestine

    1-food versus 6-food elimination diet therapy for the treatment of eosinophilic esophagitis: A multicenter, ran-domized, open-label trial

    Lancet Gastroenterol Hepatol. 2023;8(5):408−21

    Kliewer KL, Gonsalves N, Dellon ES, Katzka DA, Abonia JP, Aceves SS, Arva NC, Besse JA, Bonis PA, Caldwell JM, Capocelli KE, Chehade M, Cianfer-oni A, Collins MH, Falk GW, Gupta SK, Hirano I, Krischer JP, Leung J, Martin LJ, Menard-Katcher P, Mukkada VA, Peterson KA, Shoda T, Rudman Spergel AK, Spergel JM, Yang GY, Zhang X, Furuta GT, Rothenberg ME

    Go to article

    Esophagus to Small Intestine

    Cold snare EMR for the removal of large duodenal adenomas

    Gastrointest Endosc. 2023;97(6):1100−8

    Wang H, Sidhu M, Gupta S, Cronin O, O’Sullivan T, Whitfield A, Burgess NG, Bourke MJ

    Go to article

    Esophagus to Small Intestine

    Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or meta-static esophageal squamous cell carcinoma (RATIONALE-306): A global, randomized, placebo-controlled, phase 3 study

    Lancet Oncol. 2023;24(5):483−95

    Xu J, Kato K, Raymond E, Hubner RA, Shu Y, Pan Y, Park SR, Ping L, Jiang Y, Zhang J, Wu X, Yao Y, Shen L, Kojima T, Gotovkin E, Ishihara R, Wyrwicz L, Van Cutsem E, Jimenez-Fonseca P, Lin CY, Wang L, Shi J, Li L, Yoon HH

    Go to article

    Esophagus to Small Intestine

    Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced un-resectable or metastatic gastric or gastroesophageal junction adenocarcinoma (SPOTLIGHT): A multicenter, ran-domized, double-blind, phase 3 trial

    Lancet. 2023;401(10389):1655−68

    Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, Van Cutsem E, Xu RH, Aprile G, Xu J, Chao J, Pazo-Cid R, Kang YK, Yang J, Moran D, Bhattacharya P, Arozullah A, Park JW, Oh M, Ajani JA

    Go to article

    Esophagus to Small Intestine

    Dual antiplatelet therapy does not increase bleeding risk in percutaneous gastrostomy tube placement: Network meta-analysis

    Dig Dis Sci. 2023;68(5):1966−74

    Gangwani MK, Aziz M, Aziz A, Priyanka F, Patel A, Ghaffar U, Weissman S, Asif M, Lee-Smith W, Javaid T, Nawras A, Hart B

    Go to article

    Esophagus to Small Intestine

    Efficacy and safety of drugs for gastroparesis: Systematic review and network meta-analysis

    Gastroenterology. 2023;164(4):642–54

    Ingrosso MR, Camilleri M, Tack J, Ianiro G, Black CJ, Ford AC

    Go to article

    Esophagus to Small Intestine

    Real-world evidence comparing vedolizumab and ustekinumab in anti-tumor necrosis factor-experienced patients with Crohn’s disease

    Am J Gastroenterol. 2023;118(4):674−84

    Kappelman MD, Adimadhyam S, Hou L, Wolfe AE, Smith S, Simon AL, Moyneur É, Reynolds JS, Toh S, Dobes A, Parlett LE, Haynes K, Selvan M, Ma Q, Nair V, Burris J, Dorand JE, Dawwas GK, Lewis JD, Long MD

    Go to article

    Esophagus to Small Intestine

    Comparison of 2 strategies for the management of postoperative recurrence in Crohn’s disease patients with 1 clin-ical risk factor: A multicenter IG-IBD study

    United European Gastroenterol J. 2023;11(3):271−81

    Dragoni G, Castiglione F, Bezzio C, Pugliese D, Spagnuolo R, Viola A, Cocomazzi F, Aratari A, Savarino EV, Balestrieri P, Onali S, Viganò C, Ribaldone DG, Innocenti T, Testa A, Saibeni S, Privitera G, Milla M, Armuzzi A, Fantini MC, Fiorino G

    Go to article